Dino Di Carlo

Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.

Forcyte Biotechnologies is putting the Focus On Force in disease. As mechanical force underlies important processes in all cells, it is a key functional component driving various diseases - (asthma, hypertension, preterm labor, intestinal dysmotility, many others). Forcyte is commercializing the (UCLA-developed) FLECS Technology Platform for high-throughput analysis of contractile cell force. We develop assays, build hardware, supply software, and perform services to functionally characterize cellular force in high-throughput, down to the single-cell level! Our mission is to: 1) enable the budding field of "Force Biology"​ to automate their data collection in a standardized format to allow for direct comparison between studies, and to ultimately remove the barriers to entry for all researchers 2) provide functional high-throughput data on cellular force to support drug development in pharma, including phenotypic drug discovery, functional quantification / dose-response, toxicology, off-target effects, and general confirmation that desired contractile function is ultimately achieved See our website for more info!

Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology. Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.

Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have entered the patient bloodstream. These CTCs are known to be the key cause of secondary tumors in patients. As a result, the number and type of CTCs in a patient blood is highly indicative of the status of cancer in that patient. CTCs provide insight into the source of the primary tumor, grade, invasiveness, response to therapy and recurrence. As an indication, approximately 1.5 million new cancer patients are diagnosed per year in the United States, and around 20 million existing patients are undergoing monitoring. Vortex Biosciences has a mission to be the innovation leader in CTC capture technology delivering diagnostic tests that improve therapeutic decisions and save lives. We have introduced the VTX-1 Liquid Biopsy System which automates the isolation and collection of CTCs from blood samples. Our platform has the potential to revolutionize cancer diagnosis leading to better therapeutic outcomes. Further potential applications include clinical research and the identification of cancer therapies and drug targets. To learn more about this transformative technology, please visit our website at www.vortexbiosciences.com

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale Subscribe to our newsletter: http://eepurl.com/huCdiH

Partillion Bioscience is an early stage life science company aiming to democratize advanced single-cell assays with its award-winning nanovial platform. Our novel platform allows the rapid compartmentalization and analysis of millions of single cells to probe biological function such as secreted proteins. The validated technology underpinning Partillion’s products has been featured in notable journals such as Science Advances, Advanced Functional Materials, and Lab on Chip and received industry accolades, winning the 2020 SLAS Innovation Award.

Forcyte Biotechnologies is putting the Focus On Force in disease. As mechanical force underlies important processes in all cells, it is a key functional component driving various diseases - (asthma, hypertension, preterm labor, intestinal dysmotility, many others). Forcyte is commercializing the (UCLA-developed) FLECS Technology Platform for high-throughput analysis of contractile cell force. We develop assays, build hardware, supply software, and perform services to functionally characterize cellular force in high-throughput, down to the single-cell level! Our mission is to: 1) enable the budding field of "Force Biology"​ to automate their data collection in a standardized format to allow for direct comparison between studies, and to ultimately remove the barriers to entry for all researchers 2) provide functional high-throughput data on cellular force to support drug development in pharma, including phenotypic drug discovery, functional quantification / dose-response, toxicology, off-target effects, and general confirmation that desired contractile function is ultimately achieved See our website for more info!

Tempo Therapeutics, headquartered in San Diego, California, is pioneering a new era in tissue engineering biotechnology, using our proprietary MAP material science technology. Using MAP technology, Tempo is building functional tissue and organs within patients, in real time, to treat disease, and developing next-generation vaccine technologies that are shelf stable, stockpile-able, and protect against multiple diseases with a single injection. Our mission is to use MAP material technology to enable the future of medicine.